Study of tau pathology in male rTg4510 mice fed with a curcumin derivative Shiga-Y5.

Intracellular inclusions of aggregated tau appear in neurons and glial cells in a range of neurodegenerative diseases known as tauopathies. Inhibition of pathological changes in tau is a therapeutic target for tauopathy. We recently synthesized a novel curcumin derivative, named Shiga-Y5, and showed...

Full description

Bibliographic Details
Main Authors: Daijiro Yanagisawa, Hamizah Shahirah Hamezah, Lina Wati Durani, Hiroyasu Taguchi, Ikuo Tooyama
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0208440
id doaj-98de34af1de442fdaa9a3ba6c0e311d5
record_format Article
spelling doaj-98de34af1de442fdaa9a3ba6c0e311d52021-03-03T21:03:54ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-011312e020844010.1371/journal.pone.0208440Study of tau pathology in male rTg4510 mice fed with a curcumin derivative Shiga-Y5.Daijiro YanagisawaHamizah Shahirah HamezahLina Wati DuraniHiroyasu TaguchiIkuo TooyamaIntracellular inclusions of aggregated tau appear in neurons and glial cells in a range of neurodegenerative diseases known as tauopathies. Inhibition of pathological changes in tau is a therapeutic target for tauopathy. We recently synthesized a novel curcumin derivative, named Shiga-Y5, and showed that Shiga-Y5 inhibited cognitive impairment and amyloid deposition in a mouse model of Alzheimer's disease. Here we investigated whether Shiga-Y5 inhibited cognitive impairment and tau accumulation in a mouse model of tauopathy, rTg4510. The rTg4510 mouse is a bitransgenic mouse model that uses a system of responder and activator transgenes to express human four-repeat tau with the P301L mutation. This strain is obtained by crossing tetO-MAPT*P301L mouse line (on a FVB/NJ background) with CaMKII-tTA mouse line (on a C57BL/6J background). Male rTg4510 mice and wild-type mice were fed with a standard chow diet with or without Shiga-Y5 (500 ppm) for 4 months. Behavioral tests were conducted from 5.5 months of age, and the mice were sacrificed at 6 months of age. There were no significant changes in behavioral performance in rTg4510 mice fed with SY5-containing chow diet compared with rTg4510 mice fed with control chow diet. Histological and biochemical analyses also showed no significant alterations in tau accumulation by the treatment with SY5. One of noticeable finding in this study was that rTg4510 mice on a F1 female FVB/NJ x male C57BL/6J background showed more severe tau accumulation than rTg4510 mice on a F1 female C57BL/6J x male FVB/NJ background. Further studies to clarify the mechanisms underlying tau aggregation may help to develop therapeutic approaches aimed at preventing this pathological feature.https://doi.org/10.1371/journal.pone.0208440
collection DOAJ
language English
format Article
sources DOAJ
author Daijiro Yanagisawa
Hamizah Shahirah Hamezah
Lina Wati Durani
Hiroyasu Taguchi
Ikuo Tooyama
spellingShingle Daijiro Yanagisawa
Hamizah Shahirah Hamezah
Lina Wati Durani
Hiroyasu Taguchi
Ikuo Tooyama
Study of tau pathology in male rTg4510 mice fed with a curcumin derivative Shiga-Y5.
PLoS ONE
author_facet Daijiro Yanagisawa
Hamizah Shahirah Hamezah
Lina Wati Durani
Hiroyasu Taguchi
Ikuo Tooyama
author_sort Daijiro Yanagisawa
title Study of tau pathology in male rTg4510 mice fed with a curcumin derivative Shiga-Y5.
title_short Study of tau pathology in male rTg4510 mice fed with a curcumin derivative Shiga-Y5.
title_full Study of tau pathology in male rTg4510 mice fed with a curcumin derivative Shiga-Y5.
title_fullStr Study of tau pathology in male rTg4510 mice fed with a curcumin derivative Shiga-Y5.
title_full_unstemmed Study of tau pathology in male rTg4510 mice fed with a curcumin derivative Shiga-Y5.
title_sort study of tau pathology in male rtg4510 mice fed with a curcumin derivative shiga-y5.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2018-01-01
description Intracellular inclusions of aggregated tau appear in neurons and glial cells in a range of neurodegenerative diseases known as tauopathies. Inhibition of pathological changes in tau is a therapeutic target for tauopathy. We recently synthesized a novel curcumin derivative, named Shiga-Y5, and showed that Shiga-Y5 inhibited cognitive impairment and amyloid deposition in a mouse model of Alzheimer's disease. Here we investigated whether Shiga-Y5 inhibited cognitive impairment and tau accumulation in a mouse model of tauopathy, rTg4510. The rTg4510 mouse is a bitransgenic mouse model that uses a system of responder and activator transgenes to express human four-repeat tau with the P301L mutation. This strain is obtained by crossing tetO-MAPT*P301L mouse line (on a FVB/NJ background) with CaMKII-tTA mouse line (on a C57BL/6J background). Male rTg4510 mice and wild-type mice were fed with a standard chow diet with or without Shiga-Y5 (500 ppm) for 4 months. Behavioral tests were conducted from 5.5 months of age, and the mice were sacrificed at 6 months of age. There were no significant changes in behavioral performance in rTg4510 mice fed with SY5-containing chow diet compared with rTg4510 mice fed with control chow diet. Histological and biochemical analyses also showed no significant alterations in tau accumulation by the treatment with SY5. One of noticeable finding in this study was that rTg4510 mice on a F1 female FVB/NJ x male C57BL/6J background showed more severe tau accumulation than rTg4510 mice on a F1 female C57BL/6J x male FVB/NJ background. Further studies to clarify the mechanisms underlying tau aggregation may help to develop therapeutic approaches aimed at preventing this pathological feature.
url https://doi.org/10.1371/journal.pone.0208440
work_keys_str_mv AT daijiroyanagisawa studyoftaupathologyinmalertg4510micefedwithacurcuminderivativeshigay5
AT hamizahshahirahhamezah studyoftaupathologyinmalertg4510micefedwithacurcuminderivativeshigay5
AT linawatidurani studyoftaupathologyinmalertg4510micefedwithacurcuminderivativeshigay5
AT hiroyasutaguchi studyoftaupathologyinmalertg4510micefedwithacurcuminderivativeshigay5
AT ikuotooyama studyoftaupathologyinmalertg4510micefedwithacurcuminderivativeshigay5
_version_ 1714818934722527232